Allurion Technologies Inc. (ALUR) Stock Analysis

Allurion Technologies Inc. (ALUR) Healthcare & Pipeline Overview

Allurion Technologies Inc. leverages cutting-edge medical technology to address obesity through its Allurion Program, which includes a unique swallowable intragastric balloon and AI-driven virtual care tools, positioning itself as a leader in the weight loss device market.

What Is the Investment Thesis for ALUR?

Allurion Technologies Inc. is strategically positioned in the growing obesity treatment market, which is projected to reach $24 billion by 2028. The Allurion Program's unique offering, including the swallowable intragastric balloon and comprehensive virtual care suite, differentiates it from traditional surgical options, appealing to a larger patient base. With a gross margin of 52.7%, the company demonstrates strong potential for profitability as it scales its operations. Additionally, the increasing prevalence of obesity globally, coupled with rising healthcare costs, creates a favorable environment for Allurion's innovative solutions. However, the company faces challenges, including a negative profit margin of -264.7%, which necessitates careful management of operational costs and strategic investments to drive growth and achieve sustainable profitability.

Based on FMP financials and quantitative analysis

ALUR Key Highlights

Market Cap: $0.00B, indicating a need for growth and investment.

• Profit Margin: -264.7%, highlighting current financial challenges.
• Gross Margin: 52.7%, demonstrating potential for profitability as operations scale.
• Beta: -0.46, suggesting lower volatility compared to the market.
• No dividend yield, indicating a focus on reinvestment for growth.

Who Are ALUR's Competitors?

ALUR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ALUR's Key Strengths?

Innovative product offerings with the Allurion Balloon.

• Strong gross margin of 52.7%, indicating potential for profitability.
• Comprehensive virtual care suite enhances patient experience.
• Established presence in the growing obesity treatment market.

What Are ALUR's Weaknesses?

Negative profit margin of -264.7%, indicating financial challenges.

• Limited brand recognition compared to larger competitors.
• Dependence on a single product line for revenue generation.
• Current trading on OTC markets may limit investor interest.

What Could Drive ALUR Stock Higher?

Expansion into international markets to capture growing demand for obesity treatments.

• Development of additional features in the Allurion Virtual Care Suite to enhance patient engagement.
• Strategic partnerships with healthcare providers to broaden access to Allurion's offerings.

What Are the Key Risks for ALUR?

Financial-distress signal — its Altman Z-Score of -36.56 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Regulatory challenges that may impact product approval and market entry.
• Intense competition from established medical device companies in the obesity treatment space.
• Economic downturns affecting consumer spending on healthcare solutions.

What Are the Growth Opportunities for ALUR?

• Growth opportunity 1: The global weight loss market is projected to reach $24 billion by 2028, driven by increasing obesity rates and healthcare costs. Allurion's unique non-invasive solutions, such as the Allurion Balloon, can capture a significant share of this market, particularly among patients seeking alternatives to surgical procedures.
• Growth opportunity 2: Expansion into international markets presents a substantial opportunity for Allurion Technologies Inc. As obesity rates rise globally, particularly in regions like Europe and Asia, the company can leverage its innovative platform to address diverse patient needs and preferences, enhancing its market presence.
• Growth opportunity 3: The integration of AI-powered remote monitoring tools within the Allurion Program enhances patient engagement and adherence to weight loss protocols. This technological advancement not only improves patient outcomes but also positions Allurion as a leader in digital health solutions, attracting partnerships with healthcare providers and payers.
• Growth opportunity 4: Collaborations with healthcare systems and insurance providers can facilitate broader access to Allurion's offerings. By establishing partnerships that promote reimbursement for the Allurion Program, the company can increase patient adoption and drive revenue growth.
• Growth opportunity 5: Continuous innovation in product development, including enhancements to the Allurion Balloon and the Virtual Care Suite, can differentiate Allurion from competitors. Investing in research and development to improve efficacy and patient experience will support long-term growth and market leadership.

What Opportunities Does ALUR Have?

• Expanding global market for obesity treatment solutions.
• Potential partnerships with healthcare providers and insurers.
• Growing demand for non-invasive medical devices.
• Technological advancements in AI and telehealth can enhance offerings.

What Are ALUR's Competitive Advantages?

• Unique swallowable intragastric balloon differentiates Allurion from competitors.
• Comprehensive virtual care suite enhances patient engagement and outcomes.
• Strong focus on behavioral change supports long-term weight loss success.
• Innovative use of AI in remote monitoring provides a competitive edge.
• Established brand reputation in the obesity treatment market.

What Does ALUR Do?

Founded in Natick, Massachusetts, Allurion Technologies Inc. is dedicated to combating obesity through innovative medical solutions. The company has developed the Allurion Program, a comprehensive weight loss platform that includes a swallowable, procedure-less intragastric balloon known as the Allurion Balloon. This unique device allows patients to achieve significant weight loss without the need for invasive surgical procedures, making it accessible to a broader audience. In addition to the balloon, the Allurion Program incorporates AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth services, all delivered through the Allurion Virtual Care Suite. This holistic approach not only facilitates weight loss but also supports long-term behavioral changes, enhancing patient outcomes. Over the years, Allurion has positioned itself as a pioneer in the obesity treatment market, focusing on non-invasive solutions that empower patients to take control of their health. The company continues to evolve, expanding its services and geographic reach to meet the growing demand for effective weight loss solutions in an increasingly health-conscious society.

What Products and Services Does ALUR Offer?

• Develops a weight loss platform aimed at treating obesity.
• Offers a swallowable intragastric balloon for non-invasive weight loss.
• Provides AI-powered remote patient monitoring tools.
• Delivers a proprietary behavior change program to support weight loss.
• Facilitates secure messaging and video telehealth services.
• Focuses on empowering patients to manage their weight effectively.

How Does ALUR Make Money?

• Generates revenue through the sale of the Allurion Balloon and associated services.
• Offers subscription-based access to the Allurion Virtual Care Suite.
• Collaborates with healthcare providers and insurers for reimbursement models.
• Utilizes data analytics to enhance patient engagement and retention.
• Focuses on scaling operations to achieve economies of scale.

What Industry Does ALUR Operate In?

The medical devices industry, particularly in obesity treatment, is experiencing significant growth due to rising obesity rates and increasing awareness of health issues associated with being overweight. The global weight loss market is projected to grow at a CAGR of 8.3% from 2021 to 2028, reaching approximately $24 billion. Allurion Technologies Inc. operates within this expanding market, offering innovative solutions that cater to the growing demand for non-invasive weight loss options. The competitive landscape includes both traditional surgical methods and emerging non-surgical alternatives, positioning Allurion as a key player in this evolving sector.

Who Are ALUR's Key Customers?

• Individuals seeking non-invasive weight loss solutions.
• Healthcare providers looking for effective obesity treatment options.
• Insurance companies interested in covering innovative weight loss programs.
• Clinics and hospitals aiming to expand their weight management services.
• Health-conscious consumers focused on improving their overall wellness.

Company Profile

Allurion Technologies Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Natick, US. The company is led by CEO Shantanu K. Gaur. ALUR has traded publicly since 2021.

Return on equity for Allurion Technologies Inc. stands at 44.2%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.30 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -31.2%, the inverse of the P/E and a quick read on earnings relative to price.

ALUR Valuation & Market Position

Analyst price targets span from $3.00 to $3.00, with a consensus of $3.00. At the current price of $1.17, that implies approximately 156% upside potential.

Quarterly Financial Performance: Allurion Technologies Inc.

Revenue for Allurion Technologies Inc. came in at $2.9M during Q1 FY2026, a 18.4% contraction versus the preceding quarter. The company recorded a net loss of $6.1M, with diluted EPS of $-6.85. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, ALUR averaged $-14.09 in diluted EPS.

Allurion Technologies Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -36.56 places it in the distress zone, a signal of elevated financial risk.

Allurion Technologies Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 125.6% below estimates on average.

Over the past six months, Allurion Technologies Inc. insiders filed 6 SEC Form 4 transactions — 2 sales and 4 purchases. On net that is roughly 182K shares acquired (about $18) — insiders putting money in tends to read as conviction.

ALUR Financials

ALUR Latest News

ALUR Analyst Consensus

ALUR MoonshotScore

Common Questions About ALUR (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources